IP Library Granted Patent US 12,053,546
Granted Patent B2
US 12,053,546 · App. 13/537,646 · Granted Aug 6, 2024

Stabilized topical formulations containing core-shell microcapsules

Inventors: Ofer Toledano (Kfar Saba, IL); Haim Bar-Simantov (Netanya, IL); Hanan Sertchook (Gedera, IL)
Assignee: Sol-Gel Technologies Ltd.
A61K9/107A61K9/0014A61K9/06A61K9/501A61K9/5084A61K31/203A61K31/327A61K47/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,053,546
App. No.
13/537,646
Granted
Aug 6, 2024
Kind
B2
Abstract

The present disclosure relates to compositions for topical application, where the compositions comprise microcapsules having a core that comprises benzoyl peroxide and a shell that comprises an inorganic polymer, microcapsules having a core that comprises a retinoid and a shell that comprises an inorganic polymer, and a stabilizing agent. The composition can be in a variety of forms, such as emulsion and gel.

Claims (35)

1. A topical pharmaceutical composition, comprising:

a plurality of first core-shell microcapsules comprising a first core that comprises benzoyl peroxide and a first shell that comprises a first inorganic polymer, wherein said benzoyl peroxide is in an amount of from about 1% to about 6% by weight based on total weight of the composition, and benzoyl peroxide is the only active agent in said first core; and

a plurality of second core-shell microcapsules comprising a second core that comprises an oil phase comprising all-trans retinoic acid (ATRA) dispersed in said oil phase and at least one phase changing material, wherein said phase changing material is confined to said second core; and a second shell that comprises a second inorganic polymer, wherein said ATRA is in an amount of from about 0.05% to about 0.5% by weight based on total weight of the composition; wherein ATRA is the only active agent in said second core;

wherein the concentration of said phase changing material is less than about 10% by weight based on total weight of the composition;

wherein said phase changing material prevents the leaching of said ATRA from said core into said composition at room temperature;

wherein said ATRA is stable during the three months storage at 25° C.; and

wherein said composition is an oil in water emulsion comprising a polyoxylstearate and a glycerylstearate wherein the ratio of said polyoxylstearate to said glycerylstearate is in the range of 2:3 to 3:2;

wherein said phase changing material is not liquid at room temperature; and

wherein said second core has a viscosity of from about 5000 cP to about 1,000,000 cP.

2. The composition in accordance with claim 1 , further comprising:

an amount of an anti-microbial agent that is effective to: maintain the microbial count of the composition at a level that meets the criteria of USP 51, as measured by Antimicrobial Effectiveness Testing (AET) after storage of the composition at a storage condition of 40° C. for one month.

3. The composition in accordance with claim 2 , wherein:

said first shell comprises a first silica polymer;

said second core comprises an oil phase comprising all-trans retinoic acid (ATRA) dispersed in said oil phase and at least one phase changing material; and

said second shell comprises a second silica polymer.

4. The composition in accordance with claim 2 , wherein:

in said first core-shell microcapsules, said first shell comprises a first silica polymer, and the benzoyl peroxide is present in the composition in an initial amount of about 6% by weight, based on the total weight of the composition;

in said second core-shell microcapsules, said second core comprises an oil phase comprising all-trans retinoic acid (ATRA) dispersed in said oil phase and at least one phase changing material, and said second shell comprises a second silica polymer, the ATRA being present in the composition in an initial amount of about 0.1% by weight, based on the total weight of the composition; and

said antimicrobial agent is selected from the group consisting of methylparaben and imidazolidinyl urea.

5. The composition in accordance with claim 2 , wherein:

in said first core-shell microcapsules, said first shell comprises a first silica polymer, the benzoyl peroxide being present in the composition in an initial amount of about 3% by weight, based on the total weight of the composition;

in said second core-shell microcapsules, said second core comprises an oil phase comprising all-trans retinoic acid (ATRA) dispersed in said oil phase and at least one phase changing material, and said second shell comprises a second silica polymer, the ATRA being present in the composition in an initial amount of about 0.05% by weight, based on the total weight of the composition.

6. The composition in accordance with claim 1 , wherein at least one phase changing material is selected from the group consisting of a natural paraffin, a synthetic paraffin, an aliphatic alcohol, a fatty acid, C 10 -C 100 alkanes, C 10 -C 100 alkenes, C 10 -C 100 alkynes, carnauba wax, beeswax, and a mixture thereof.

7. The composition in accordance with claim 1 , wherein said polyoxylstearate is selected from the group consisting of Polyoxyl-8 stearate, Polyoxyl-20 stearate, Polyoxyl-40 stearate, and Polyoxyl-100 stearate.

8. The composition in accordance with claim 1 , wherein said glycerylstearate is selected from the group consisting of glyceryl mono-stearate, glyceryl di-stearate and mixtures thereof.

9. The composition in accordance with claim 1 , wherein the amount of said polyoxylstearate in said composition is in the range of 0.1% w/w to 30% w/w.

10. The composition in accordance with claim 1 , wherein the amount of said glycerylstearate in said composition is in the range of 0.1% w/w to 30% w/w.

11. The composition in accordance with claim 1 , wherein said composition further comprises at least one fatty alcohol.

12. The composition in accordance with claim 11 , wherein said at least one fatty alcohol is selected from the group consisting of octyl alcohol, 2-ethyl hexanol, nonyl alcohol, decyl alcohol, undecanol, dodecyl alcohol, tridecyl alcohol, tetradecyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoleyl alcohol, heptadecyl alcohol, cetostearyl alcohol, stearyl alcohol, isostearyl alcohol, elaidyl alcohol, oleyl alcohol, linoleyl alcohol, elaidolinolenyl alcohol, ricinoleyl alcohol, nonadecyl alcohol, arachidyl alcohol, heneicosyl alcohol, behenyl alcohol, erucyl alcohol, lignoceryl alcohol, ceryl alcohol, montanyl alcohol, cluytyl alcohol, myricyl alcohol, melissyl alcohol, geddyl alcohol, cetearyl alcohol and mixtures thereof.

13. The composition in accordance with claim 12 , wherein the amount of said at least one fatty alcohol in said composition is in the range of 0.2% w/w to 50% w/w.

14. The composition in accordance with claim 1 , wherein said composition further comprises a polyacrylic acid homopolymer or copolymer.

15. The composition in accordance with claim 1 , wherein said oil in said oil in water emulsion is selected from the group consisting of paraffin oil, isopropyl myristate, caprylic/capric triglyceride, squalane, squalene, almond oil, castor oil, olive oil, jojoba oil, sunflower oil, soybean oil, grape seed oil, dimethicone, cyclomethicone and mixtures thereof.

16. The composition in accordance with claim 15 , wherein said oil is present in the composition in an amount in the range of 0.05% w/w to 50% w/w.

17. The composition in accordance with claim 1 , wherein said water in said oil in water emulsion further comprises at least one water soluble humectant.

18. The composition in accordance with claim 17 , wherein said at least one water soluble humectant is selected from the group consisting of propylene glycol, glycerin, and polyethylene glycol-X, where X is in the range of 200 to 10,000.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2025
From: SOL-GEL TECHNOLOGIES LTD.
To: MAYNE PHARMA LLC
Reel/Frame 071148/0446 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2017
From: SERTCHOOK, HANAN
To: SOL-GEL TECHNOLOGIES LTD.
Reel/Frame 043255/0994 →
CORRECTIVE ASSIGNMENT TO CORRECT THE LIST OF PROPERTIES IN THE RECORDED DOCUMENT PREVIOUSLY RECORDED ON REEL 034749 FRAME 0689. ASSIGNOR(S) HEREBY CONFIRMS THE LISTED PROPERTIES ERRONEOUSLY INCLUDED APPLN 13/537,646 (SEE PP 26-27 OF CORRECTED DOC). Recorded Jul 26, 2016
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 039466/0001 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 22, 2014
From: SOL- GEL TECHNOLOGIES LTD.
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 032014/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2014
From: MEDICIS PHARMACEUTICAL CORPORATION
To: SOL-GEL TECHNOLOGIES LTD.
Reel/Frame 032014/0694 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 22, 2014
From: TOLEDANO, OFER; BAR-SIMANTOV, HAIM
To: SOL- GEL TECHNOLOGIES LTD.
Reel/Frame 032014/0567 →
RELEASE OF SECURITY INTEREST Recorded Jan 15, 2014
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 031974/0643 →
SECURITY AGREEMENT Recorded Apr 24, 2013
From: MEDICIS PHARMACEUTICAL CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC
Reel/Frame 030281/0433 →
Continuity (2)
Provisional Application 61502725 · Jun 29, 2011
Related Publication 20130095185A1 · Apr 18, 2013
Cited By (1)
US 12,357,602